Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.12.015
Abstract: OBJECTIVE To evaluate total and out-of-pocket costs for poly(ADP-ribose) polymerase (PARP) inhibitors and differences based on insurance characteristics. METHODS We identified ovarian cancer patients who were prescribed niraparib, olaparib, or rucaparib from the MarketScan (2014-2017)… read more here.
Keywords: parp inhibitors; pocket costs; ovarian cancer; total pocket ... See more keywords